New Bosnia/Herzegovina law "potential disaster"

25 July 2006

Bosnia and Herzegovina's top pharmaceutical body has claimed that a new law on medicines could lead to "disaster" for the population. The Inter-Cantonal Pharmaceutical Chamber of the Muslim-Croat Federation of Bosnia and Herzegovina has called for 35 proposed amendments to the state law on Medicines and Medical Equipment that will soon to be adopted.

Particular concerns about import checks

The Chamber has warned that the new law poorly defines controls in certain areas. One particular concern that it has is with checks on imported medicines. It says that the legislation suggests that imported medicines will not be independently checked by local bodies but by producers instead. Chamber president Madjira Pavlovic-Konjicanin said: "this could cause the appearance of harmful medicines in the Bosnian market and, if imported medicines do not correspond to the declarations of producers or importers, the consequences for the population could be disastrous."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight